#Mobocertinib
LightNews LightNews
rielymd.bsky.social
Full publication of phase 3 that compared mobocertinib to platinum-pem in EGFR exon 20 lung cancer. Ultimately led to mobocertinib removal from market. This remains the goal: new drugs should be better than chemotherapy. We should not settle for adding to chemotherapy!
ascopubs.org/doi/pdf/10.1...
kaplan-meier curves showing (A) equivalent PFS for mobocertinib and chemotherpy (C) improved duration of response for mobocertinib
January 30, 2025 at 2:20 PM
iebpharma.bsky.social
Moboxen 40mg (Mobocertinib) We assure you that all of our products are genuine. We pledge to maintain our steady effectiveness.
#Moboxen40mg #Mobocertinib #Medicine #Health #OnlineMedicine #Antiviral #AntiCancer #LiverCancer #pharmacy
iebpharma.com/product/mobo...
Moboxen 40mg (Mobocertinib) | Worldwide Shipping
Moboxen 40mg, known as mobocertinib, is a targeted therapy drug primarily used to treat non-small cell lung cancer (NSCLC) that has certain genetic abnormalities.
iebpharma.com
May 14, 2024 at 3:48 PM
ascopost.bsky.social
The #EXCLAIM2 trial found no progression-free survival benefit for mobocertinib vs platinum chemotherapy in first-line treatment of advanced NSCLC. Both had median PFS of 9.6 months. Mobocertinib showed longer response duration but more AEs. ascopost.com/news/februar...
#LungCancer
February 13, 2025 at 4:03 PM
rridrobot.bsky.social
RRIDs were included in this in European Journal of Cancer paper. Thanks for making your methods matter! #methodsmatter #BetterScience #reproducibility
Phase Ia/Ib trial of the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M)
Read the full paper: Phase Ia/Ib trial of the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M)
doi.org
March 21, 2026 at 7:00 AM
iebpharma.bsky.social
Global Shipping: International online pharmacies typically offer worldwide shipping, allowing customers to receive their orders regardless of their location.
#Moboxen40mg #Mobocertinib40mg #Medicine #Health #OnlineMedicine #MedicineStore #AntiCancer #LiverCancer
iebpharma.com/product/mobo...
Moboxen 40mg (Mobocertinib) | Worldwide Shipping
Moboxen 40mg, known as mobocertinib, is a targeted therapy drug primarily used to treat non-small cell lung cancer (NSCLC) that has certain genetic abnormalities.
iebpharma.com
May 11, 2024 at 3:49 PM
hhorinouchi.bsky.social
🔥 @ascocancer.bsky.social Journal of Clinical Oncology 🆙
✅EXCLAIM-2: First-Line Mobocertinib vs Chemo in Pts with EGFR Exon 20 Insertion-Positive Metastatic NSCLC
🎯PFS hazard ratio 1.04 [95% CI, 0.77 to 1.39]
👥Dr. Pasi A Jänne
#LCSM @oncoalert.bsky.social
ascopubs.org/doi/10.1200/...
First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With <i>EGFR</i> Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial
PURPOSEMobocertinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that targets EGFR exon 20 insertion (ex20ins) mutations in non–small cell lung cancer (NSCLC). This ope...
ascopubs.org
February 1, 2025 at 2:32 PM
rridrobot.bsky.social
RRIDs were included in this in Frontiers in Oncology paper. RRIDs improve reproducibility in scientific research. #accelerateopenscience #ReproducibleResearch #OpenResearch
Frontiers | Paired ctDNA analysis reveals diverse resistance mechanisms to mobocertinib in EGFR exon 20 insertion NSCLC
BackgroundEpidermal growth factor receptor (EGFR) exon 20 insertion mutations in non-small cell lung cancer (NSCLC) represent a distinct molecular subset wit...
doi.org
June 6, 2026 at 7:02 AM
realbiomassspec.bsky.social
A Simple and Sensitive LC-MS/MS Method for the Determination of Mobocertinib and Its Metabolite Desmethyl-Mobocertinib in Human Plasma and Its Application to Clinical Pharmacokinetic Study #BiomedChrom analyticalsciencejournals.onlinelibrary.wiley.com/doi/full/10....
A Simple and Sensitive LC‐MS/MS Method for the Determination of Mobocertinib and Its Metabolite Desmethyl‐Mobocertinib in Human Plasma and Its Application to Clinical Pharmacokinetic Study
Mobocertinib is a potent selective tyrosine kinase inhibitor approved for the treatment of non–small cell lung cancer with activating EGFR exon 20 insertions. The aim of this study was to develop a p...
analyticalsciencejournals.onlinelibrary.wiley.com
January 3, 2025 at 8:46 AM
stevenartandi.bsky.social
SCI member Joel Neal & others found mobocertinib is not superior to platinum-based chemotherapy in treating EGFR ex20ins+ advanced/metastatic #NSCLC. No significant difference in progression-free survival, but mobocertinib showed longer response duration. pubmed.ncbi.nlm.nih.gov/39879577/
June 27, 2025 at 4:07 PM
lungenforschung.bsky.social
Mehr erfahren: doi.org/10.1200/JCO-...
First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With <i>EGFR</i> Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial
PURPOSEMobocertinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that targets EGFR exon 20 insertion (ex20ins) mutations in non–small cell lung cancer (NSCLC). This open-label, phase III trial (EXCLAIM-2: ClinicalTrials.gov ...
doi.org
February 25, 2025 at 12:09 PM
lungenforschung.bsky.social
📢 EXCLAIM-2: Mobocertinib vs. Chemo bei EGFR ex20ins+ NSCLC – keine Überlegenheit bei progressionsfreiem Überleben (9,6 Monate in beiden Gruppen). Nebenwirkungsprofil und QoL unterschieden sich. Fazit: Keine Empfehlung als Erstlinientherapie. 🔬🚨 #Lungenkrebs #Onkologie
February 25, 2025 at 12:09 PM
iebpharma.bsky.social
These pharmacies provide a convenient option for people to access a wide range of pharmaceuticals without the need to visit a physical store.
#Mobonib40mg #Mobocertinib40mg#Medicine #Health #OnlineMedicine #MedicineStore #AntiCancer #LiverCancer
iebpharma.com/product/mobo...
Mobocertinib 40 Mg (Mobonib) | Order Now At IEB Pharma
A medicine known as Mobocertinib 40 Mg (Mobonib) is a targeted treatment for certain types of non-small cell lung cancer (NSCLC).
iebpharma.com
May 11, 2024 at 3:39 PM
iebpharma.bsky.social
Moboxen 40mg, also known by its generic name Mobocertinib, is a medication primarily used for the treatment of non-small cell lung cancer (NSCLC).
#Moboxen40mg #Mobocertinib #Medicine #Health #OnlineMedicine #MedicineStore #AntiCancer #LiverCancer
iebpharma.com/product/mobo...
April 10, 2024 at 10:30 AM
iebpharmabd.bsky.social
Mobocertinib is a type of drug called a kinase inhibitor, which is used to treat a rare type of non-small cell lung cancer (NSCLC).
iebpharma.com/product/deuc...
#Mobocertinib40Mg #Mobonib #IebPharma #AntiCancer #AntiViral #BreastCancer #KidneyCancer #LiverCancer
Best Deucrava 6 Mg (Deucravacitinib) | Worldwide Shipping
After Deucrava 6 Mg (Deucravacitinib) was administered once daily, the steady state Cmax and AUC24 were 45 ng/mL and 473 ng x hr/mL,
iebpharma.com
December 25, 2024 at 6:01 AM
iebpharmabd.bsky.social
Mobocertinib, Exkivity is a prescription medicine used to treat lung cancer.
#Avatropag20Mg #Avatrombopag #Maleate #IebPharma #AntiCancer #AntiViral #BreastCancer #KidneyCancer #LiverCancer
iebpharma.com/product/mobo...
Mobocertinib 40 Mg (Mobonib) | Order Now At IEB Pharma
A medicine known as Mobocertinib 40 Mg (Mobonib) is a targeted treatment for certain types of non-small cell lung cancer (NSCLC).
iebpharma.com
December 25, 2024 at 6:00 AM
medrxivpreprint.bsky.social
Evolving Ocular Safety Signals of EGFR Inhibitors: A FAERS Disproportionality Analysis of Amivantamab, Mobocertinib, and Classic Agents https://www.medrxiv.org/content/10.64898/2026.03.16.26348536v1
March 18, 2026 at 10:25 PM
alcmi.bsky.social
Our friend Dr. Pasi Jänne recently led the EXCLAIM-2 study published in the Journal of Clinical Oncology. Despite the innovative promise of mobocertinib, the trial revealed no significant advantage in progression-free survival over platinum-based chemotherapy. #lungcancer
buff.ly
February 7, 2025 at 3:00 PM
kkmurray.bsky.social
(Biomed Chrom) A Simple and Sensitive LC‐MS/MS Method for the Determination of Mobocertinib and Its Metabolite Desmethyl‐Mobocertinib in Human Plasma and Its Application to Clinical Pharmacokinetic Study: ABSTRACT

Mobocertinib is a potent… http://dlvr.it/TH8jWm #massSpecRSS #biomedchrom
January 3, 2025 at 9:05 PM